anti-Respiratory Syncytial Virus, Fusion Protein A,B antibody product blog
Tags: Antibody; Monoclonal Antibody; Respiratory Syncytial Virus, Fusion Protein A,B; anti-Respiratory Syncytial Virus, Fusion Protein A,B antibody;
The Respiratory Syncytial Virus, Fusion Protein A,B n/a (Catalog #MBS607589) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s Respiratory Syncytial Virus, Fusion Protein A,B can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA), Immunofluorescence (IF).Suitable for use in ELISA and Immunofluorescence.
Dilution: ELISA: 1:20-1:200
Immunofluorescence: 1:10-1:50. Researchers should empirically determine the suitability of the Respiratory Syncytial Virus, Fusion Protein A,B n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
RSV is a negative-sense, single-stranded RNA virus and is a member of the Paramyxoviridae family. RSV causes respiratory tract infections in patients of all ages, but particularly affects infants and the immunosuppressed. RSV encodes three envelope glycoproteins, a small hydrophobic (SH) protein of unknown function, a glycoprotein (G) known as the attachment protein, and a fusion (F) protein. The F protein directs fusion of viral and cellular membranes, resulting in viral penetration, and can lead to the formation of syncytia. The F protein is thought to be the principal antigen responsible for inducing an immune response.
Immunogen: Fusion protein of the human Respiratory Synctial Virus. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing Respiratory Syncytial Virus, Fusion Protein A,B are readily searchable from our website. Different antibodies against the same target such as Respiratory Syncytial Virus, Fusion Protein A,B may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.